初次小梁切除术与青光眼引流管植入术研究5年随访中的术后并发症
多中心随机临床试验纳入242眼药物不可控且无眼部切口手术史的青光眼患者,随机接受350-mm2 Baerveldt引流管植入或小梁切除术联合丝裂霉素C(0.4 mg/ml,2分钟)。早期并发症小梁切除组40例(34%)高于引流管组24例(19%),P=0.013;晚期并发症、严重并发症及白内障进展两组相似,并发症未增加治疗失败、视力丧失或白内障进展风险。
要点
- 早期术后并发症小梁切除组40例(34%)高于引流管组24例(19%),P=0.013。
- 晚期并发症两组分别为引流管组27例(22%)与小梁切除组32例(27%),P=0.37。
- 严重并发症引流管组3例(2%)与小梁切除组9例(8%)相比P=0.11,无统计学显著差异。
核心结论
- PTVT研究中观察到大量手术并发症,但大多数为一过性且自限。
- 小梁切除术联合MMC术后早期并发症发生率高于引流管植入术。
- 5年随访时两种手术的晚期并发症、严重并发症及白内障进展发生率相似。
- 手术并发症未增加治疗失败、视力丧失或白内障进展的风险。
研究设计与样本
- 多中心随机临床试验,纳入242例患者的242眼,其中引流管组125例、小梁切除组117例。
- 入选者为药物不可控且既往无眼部切口手术的青光眼患者,来自16个临床中心。
- 随机分组接受350-mm2 Baerveldt青光眼植入物或小梁切除术联合丝裂霉素C(0.4 mg/ml,2分钟)。
- 主要观察指标为手术并发症、因并发症再手术、视力及白内障进展,随访5年。
主要发现
- 早期术后并发症引流管组24例(19%) vs 小梁切除组40例(34%),P=0.013。
- 晚期术后并发症引流管组27例(22%) vs 小梁切除组32例(27%),P=0.37。
- 导致视力丧失和/或需再手术的严重并发症引流管组3例(2%) vs 小梁切除组9例(8%),P=0.11。
- 白内障进展引流管组65例(52%) vs 小梁切除组52例(44%),P=0.30。
- 手术并发症与治疗失败(P=0.61)、视力丧失(P=1.00)或白内障进展(P=0.77)风险无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe postoperative complications encountered in the Primary Tube Versus Trabeculectomy (PTVT) Study during 5 years of follow-up. DESIGN: Multicenter randomized clinical trial. PARTICIPANTS: A total of 242 eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 patients in the tube group and 117 patients in the trabeculectomy group. METHODS: Patients were enrolled at 16 clinical centers and randomly assigned to treatment with a tube shunt (350-mm2 Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC, 0.4 mg/ml for 2 minutes). MAIN OUTCOME MEASURES: Surgical complications, reoperations for complications, visual acuity, and cataract progression. RESULTS: Early postoperative complications occurred in 24 patients (19%) in the tube group and 40 patients (34%) in the trabeculectomy group (P = 0.013). Late postoperative complications developed in 27 patients (22%) in the tube group and 32 patients (27%) in the trabeculectomy group (P = 0.37). Serious complications producing vision loss and/or requiring a reoperation were observed in 3 patients (2%) in the tube group and 9 patients (8%) in the trabeculectomy group (P = 0.11). Cataract progression was seen in 65 patients (52%) in the tube group and 52 patients (44%) in the trabeculectomy group (P = 0.30). Surgical complications were not associated with a higher rate of treatment failure (P = 0.61), vision loss (P = 1.00), or cataract progression (P = 0.77) CONCLUSIONS: A large number of surgical complications were observed in the PTVT Study, but most were transient and self-limited. The incidence of early postoperative complications was higher following trabeculectomy with MMC than with tube shunt surgery. The rates of late postoperative complications, serious complications, and cataract progression were similar with both surgical procedures after 5 years of follow-up. Surgical complications did not increase the risk of treatment failure, vision loss, or cataract progression.
引用
- Gedde SJ, Feuer WJ, Lim KS, et al. Postoperative Complications in the Primary Tube Versus Trabeculectomy Study During 5 Years of Follow-up. Ophthalmology. 2022. PMID: 35835336. doi:10.1016/j.ophtha.2022.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。